中文網
Taipei
Thu, May 26, 2022
20:08
light rain with thunder
24°C
CONNECT WITH US
Related company info
Jay Liu, Taipei; Eifeh Strom, DIGITIMES
Friday 22 October 2021
  • Apex Biotechnology
  • Performance
    The company's stock price closed at NT$26.05 on the TSE on Wednesday, May 25, 2022.
    The company has reported consolidated revenues of NT$208 million for April 2022, representing a 18.8% increase on month and 32% increase on year.
    For the fourth quarter of 2021, the company totaled NT$561 million in consolidated revenues, up 10.2% sequentially and up 23.4% on year.
    Brief

    Full name: Apex Biotechnology

    Chinese name: 五鼎生物技術股份有限公司

    Short name: Apex

    Stock code: 1733

    Tax ID: 16130182

    Market: TSE

    Established: 2 Dec 1997

    Paid in capital: NT$997.27 million

    Listed on TSE: 17 Sep 2001

    Website: www.apexbio.com

  • Latest stock
    Apex [1733] historical stock price (NT$)
    DateVolume (k)TransactionsValueOpenHighLowCloseChangeAskBid
    26-May 690 366 17,778,708 26.20 26.20 25.55 25.60-0.45-1.73% 25.60 25.65
    25-May 240 147 6,227,987 26.00 26.05 25.85 26.05+0.05+0.19% 26.00 26.05
    23-May 160 122 4,154,579 26.00 26.20 25.90 26.10+0.10+0.38% 26.05 26.10
    20-May 261 163 6,813,798 26.20 26.20 26.00 26.00-0.10-0.38% 26.00 26.15
    19-May 444 248 11,565,385 26.00 26.30 25.95 26.10+0.00+0.00% 26.05 26.10
    18-May 462 272 12,141,581 26.20 26.60 26.10 26.10+0.00+0.00% 26.10 26.40
    17-May 663 480 17,271,600 26.00 26.45 25.90 26.10-0.05-0.19% 26.10 26.15
    • Source: TSE, compiled by Digitimes
    Latest sales

    Apex: Consolidated revenues, Apr 2021 - Apr 2022 (NT$m)

    Month

    Sales

    M/M

    Y/Y

    YTD

    Y/Y

    Apr-22

    208

    18.8%

    32%

    730

    (0.5%)

    Mar-22

    175

    (5.6%)

    0.1%

    522

    (9.4%)

    Feb-22

    186

    15.3%

    (11.7%)

    347

    (13.6%)

    Jan-22

    161

    (18.8%)

    (15.7%)

    161

    (15.7%)

    Dec-21

    198

    0.1%

    31.9%

    2,132

    6.3%

    Nov-21

    198

    19.9%

    38.5%

    1,933

    4.2%

    Oct-21

    165

    (1.5%)

    2.2%

    1,735

    1.4%

    Sep-21

    168

    (1.2%)

    11.7%

    1,570

    1.3%

    Aug-21

    170

    (1.6%)

    2.4%

    1,403

    0.2%

    Jul-21

    172

    10.5%

    (11.2%)

    1,233

    (0.2%)

    Jun-21

    156

    (8.7%)

    (30.6%)

    1,061

    1.9%

    May-21

    171

    8.4%

    (1.6%)

    905

    10.8%

    Apr-21

    158

    (9.9%)

    20.5%

    734

    14.2%

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, May 2022

    Apex: Consolidated revenues, 4Q20 - 4Q21 (NT$m)

    Quarter

    Sales

    Q/Q

    Y/Y

    YTD

    Y/Y

    4Q-21

    561

    10.2%

    23.4%

    2,132

    6.3%

    3Q-21

    509

    5.2%

    (0%)

    1,570

    1.3%

    2Q-21

    484

    (15.9%)

    (8.4%)

    1,061

    1.9%

    1Q-21

    576

    26.8%

    12.6%

    576

    12.6%

    4Q-20

    455

    (10.8%)

    (31.8%)

    2,005

    (8.8%)

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, May 2022

    Latest balance sheet and income statement

    Apex: Consolidated balance sheet, 4Q20 - 4Q21 (NT$k)

    Item

    4Q-2021

    3Q-2021

    2Q-2021

    1Q-2021

    4Q-2020

    Current assets

    1,759,853

    1,535,060

    1,705,282

    1,778,263

    1,684,472

    Intangible assets

    106,478

    112,051

    115,088

    123,172

    128,920

    Non-current assets

    910,614

    914,284

    926,466

    946,214

    966,970

    Assets

    2,670,467

    2,449,344

    2,631,748

    2,724,477

    2,651,442

    Current liabilities

    785,888

    657,086

    796,465

    923,643

    883,426

    Non-current liabilities

    131,023

    122,334

    120,075

    120,490

    121,849

    Liabilities

    916,911

    779,420

    916,540

    1,044,133

    1,005,275

    Stockholders' equity

    1,753,556

    1,669,924

    1,715,208

    1,680,344

    1,646,167

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, May 2022

    Apex: Consolidated income statement, 4Q20 - 4Q21 (NT$k)

    Item

    4Q-2021

    3Q-2021

    2Q-2021

    1Q-2021

    4Q-2020

    NT$k

    % of sales

    NT$k

    % of sales

    NT$k

    % of sales

    NT$k

    % of sales

    NT$k

    % of sales

    Operating revenue

    561,314

     

    509,469

     

    484,485

     

    576,388

     

    454,730

     

    Gross profit (loss) from operations

    145,514

    25.9%

    148,630

    29.2%

    126,900

    26.2%

    150,468

    26.1%

    106,827

    23.5%

    Operating expenses

    97,290

    17.3%

    91,489

    18%

    89,586

    18.5%

    88,198

    15.3%

    80,320

    17.7%

    Operating income (loss)

    48,224

    8.6%

    57,141

    11.2%

    37,314

    7.7%

    62,270

    10.8%

    26,507

    5.8%

    Non-operating expenses and losses

    10,069

    1.8%

    3,832

    0.8%

    -12,177

    -2.5%

    -21,737

    -3.8%

    11,859

    2.6%

    Income from continuing operations before income tax

    58,293

    10.4%

    60,973

    12%

    25,137

    5.2%

    40,533

    7%

    38,366

    8.4%

    Net income (loss)

    81,534

    14.5%

    64,162

    12.6%

    22,528

    4.6%

    34,065

    5.9%

    33,054

    7.3%

    Diluted earnings per share (NT$)

    0.8

     

    0.6

     

    0.2

     

    0.3

     

    0.3

     

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, May 2022

  • Apex Biotechnology full profile
Realtime news

Taiwan notebooks - 4Q 2021

Global server revenue forecast, 2022

Global server shipment forecast, 2022

South Korea to build semiconductor ecosystem; Tianma to invest in 8.6-gen panel project; Nissan and Honda unveil EV development plans

Advanced packaging technology outlook, 2020-2026

Smart manufacturing progress of Taiwan, 2021